2-methylbenzo[d]thiazol-5-yl cyclohexylcarbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 2-methylbenzo[d]thiazol-5-yl cyclohexylcarbamate
• 英文别名: (2-methyl-1,3-benzothiazol-5-yl) N-cyclohexylcarbamate
• 化学式: C₁₅H₁₈N₂O₂S
• 分子量: 290.386
• InChiKey: DDQNRNAYNJMRLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  79.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-甲基-5-苯并噻唑 、 环己基异氰酸酯 在 三乙胺 作用下， 以 甲苯 为溶剂， 以79%的产率得到2-methylbenzo[d]thiazol-5-yl cyclohexylcarbamate
  参考文献：
  名称：

  发现未表征水解酶抑制剂的功能蛋白质组学策略

  摘要：

  水解酶构成自然界中最大和最多样化的蛋白质类别之一，并且在几乎所有生理和病理过程中都发挥着关键作用。哺乳动物丝氨酸水解酶超家族包含大量未表征的成员，其中至少 40-50% 的酶缺乏经过实验验证的内源性底物和产物。将代谢和细胞功能分配给这些酶需要开发药理学工具来选择性地干扰它们的活性。我们在此描述了一种功能蛋白质组学策略，以系统地开发用于未表征的丝氨酸水解酶的有效和选择性抑制剂及其在大脑富集酶 α/β-水解酶-6 中的应用。

  DOI：

  10.1021/ja073650c

文献信息

• INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：Dasse Olivier

  公开号：US20070155747A1

  公开（公告）日：2007-07-05

  Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. Esters of alkylcarbamic acids are disclosed that are inhibitors of FAAH activity. Compounds disclosed herein inhibit FAAH activity. Described herein are processes for the preparation of esters of alkylcarbamic acid compounds, compositions that include them, and methods of use thereof.

  药物抑制脂肪酸酰胺水解酶（FAAH）活性会导致脂肪酸酰胺水平的增加。本文披露了烷基氨基酸酯类化合物，其可作为FAAH活性抑制剂。本文披露的化合物可抑制FAAH活性。本文还描述了制备烷基氨基酸酯类化合物的方法、包括它们的组合物以及使用它们的方法。
• METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO
  申请人：Compton R. Timothy

  公开号：US20080089845A1

  公开（公告）日：2008-04-17

  Described herein is a method for determining an effective dose of a composition for inhibiting fatty acid amide hydrolase activity in vivo, by first administering to a subject a dose of a test composition, and subsequently assessing if the level of a fatty acid amide in the subject increases. Also described, is a method for optimizing therapeutic efficacy for treatment of anxiety, depression, pain, or a metabolic disorder by increasing or decreasing a dose of a fatty amide hydrolase inhibitor according to a patient's fatty acid amide levels. In addition, pharmaceutical compositions are described, which contain fatty acid amide hydrolase inhibitors effective for increasing a FAA level in a patient.
• [EN] INHIBITORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] INHIBITEURS DE L'AMIDE HYDROLASE D'ACIDES GRAS
  申请人：KADMUS PHARMACEUTICALS INC

  公开号：WO2007079180A2

  公开（公告）日：2007-07-12

  [EN] Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. Esters of alkylcarbamic acids are disclosed that are inhibitors of FAAH activity. Compounds disclosed herein inhibit FAAH activity. Described herein are processes for the preparation of esters of alkylcarbamic acid compounds, compositions that include them, and methods of use thereof.
  [FR] La présente invention concerne l'inhibition pharmacologique de l'amide hydrolase d'acides gras (FAAH), qui conduit à un taux accru d'amides d'acides gras. La présente invention a trait à des esters d'acides alkylcarbamiques, qui inhibent l'activité de la FAAH. Les composés selon la présente invention inhibent l'activité de la FAAH. L'invention a également trait à des procédés permettant la préparation d'esters de composés d'acide alkylcarbamique, à des compositions incluant ces composés et à des procédés d'utilisation de ces composés.
• [EN] METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO<br/>[FR] PROCÉDÉS DE DÉTERMINATION DES DOSES EFFICACES DES INHIBITEURS DE L'AMIDE D'ACIDE GRAS-HYDROLASE IN VIVO
  申请人：ORGANON NV

  公开号：WO2008030752A2

  公开（公告）日：2008-03-13

  [EN] Described herein is a method for determining an effective dose of a composition for inhibiting fatty acid amide hydrolase activity in vivo, by first administering to a subject a dose of a test composition, and subsequently assessing if the level of a fatty acid amide in the subject increases. Also described, is a method for optimizing therapeutic efficacy for treatment of anxiety, depression, pain, or a metabolic disorder by increasing or decreasing a dose of a fatty amide hydrolase inhibitor according to a patient's fatty acid amide levels. In addition, pharmaceutical compositions are described, which contain fatty acid amide hydrolase inhibitors effective for increasing a FAA level in a patient.
  [FR] La présente invention concerne un procédé de détermination de la dose efficace d'une composition destinée à inhiber une activité amide d'acide gras-hydrolase in vivo, en administrant d'abord à un sujet une dose d'une composition testée et en recherchant ensuite si le taux d'un amide d'acide gras a augmenté chez le sujet. L'invention concerne également un procédé permettant d'optimiser l'efficacité thérapeutique pour le traitement de l'angoisse, de la dépression, de la douleur ou d'une affection métabolique en augmentant ou en diminuant la dose d'un inhibiteur d'amide d'acide gras-hydrolase en fonction des taux d'amides d'acide gras chez le patient. De plus, l'invention concerne des compositions pharmaceutiques qui contiennent des inhibiteurs d'amide d'acide gras-hydrolase efficaces pour augmenter le taux de FAA (Fatty Acid Amide : amide d'acide gras) chez un patient.
• A Functional Proteomic Strategy to Discover Inhibitors for Uncharacterized Hydrolases
  作者：Weiwei Li、Jacqueline L. Blankman、Benjamin F. Cravatt

  DOI：10.1021/ja073650c

  日期：2007.8.1

  potent and selective inhibitors for uncharacterized serine hydrolases and its application to the brain-enriched enzyme α/β-hydrolase-6. We anticipate that the methods described herein will facilitate the development of selective chemical probes to annotate the metabolic and (patho)physiological functions of many of the uncharacterized serine hydrolases that currently populate eukaryotic and prokaryotic

  水解酶构成自然界中最大和最多样化的蛋白质类别之一，并且在几乎所有生理和病理过程中都发挥着关键作用。哺乳动物丝氨酸水解酶超家族包含大量未表征的成员，其中至少 40-50% 的酶缺乏经过实验验证的内源性底物和产物。将代谢和细胞功能分配给这些酶需要开发药理学工具来选择性地干扰它们的活性。我们在此描述了一种功能蛋白质组学策略，以系统地开发用于未表征的丝氨酸水解酶的有效和选择性抑制剂及其在大脑富集酶 α/β-水解酶-6 中的应用。